Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 20, 2025 09:20 ET | Source: Moleculin Biotech, Inc.

Moleculin Announces $5.9 Million Public Offering

HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates...
June 04, 2025 08:45 ET | Source: Moleculin Biotech, Inc.

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed...
September 08, 2020 07:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...
August 06, 2020 07:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Second Quarter Financial Results and Corporate Updates

RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summerPhase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3...
July 08, 2020 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Dr. Golumbeski formerly led corporate and business development at Celgene and NovartisAppointment adds unique skill set to Corbus Board ahead of several key data readouts this summer Norwood, MA,...
June 22, 2020 08:00 ET | Source: Mateon Therapeutics, Inc.

MATEON AND GMP COMPLETED RESEARCH AND SERVICE AGREEMENT

- Mateon and GMP to proceed to clinical development of OT-101 and Artemisin and other antisense drug candidates against COVID-19 AGOURA HILLS, Calif., June 22, 2020 (GLOBE NEWSWIRE) --...
May 27, 2020 08:05 ET | Source: Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Topline data on schedule for summer 2020Systemic sclerosis (SSc) is a rare, serious and life-threatening autoimmune disease affecting ~200,000 people in the U.S., EU and JapanThere are no FDA-approved...
September 13, 2018 07:00 ET | Source: Breathtec Biomedical Inc.

Breathtec Provides Nash Pharmaceuticals’ Plans for Next Year

VANCOUVER, British Columbia, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI) (OTCQB: BTHCF) (the “Company”) is pleased to provide details on Nash...
March 13, 2018 09:00 ET | Source: Spotlight Innovation Inc.

Newly Issued U.S. Patent Covers Spotlight Innovation's Spinal Muscular Atrophy Drug Candidates

URBANDALE, IA, March 13, 2018 (GLOBE NEWSWIRE) -- Spotlight Innovation Inc. (OTCQB: STLT), a pharmaceutical company targeting rare, emerging and neglected diseases, today announced that U.S. Patent...